Brown / Noller / Denenberg 2019: Ibogaine Subjective Experience Follow-on to Brown–Alper & Noller OUD Cohorts (Not a Depression Cure Trial)

Definition box

Definition: Brown T.K., Noller G.E., & Denenberg J.O. (2019) published *Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder* in the *Journal of Psychoactive Drugs* (doi: 10.1080/02791072.2019.1598603; PMID 30967101). It is a qualitative / psychometric follow-on to two already-published observational OUD cohorts: Mexico participants overlapping the Brown & Alper 2018 detoxification series (doi 10.1080/00952990.2017.1320802; n=30) and New Zealand participants from Noller et al. 2018 (doi 10.1080/00952990.2017.1310218; n=14). Combined n=44 completed the States of Consciousness Questionnaire (SCQ) after oral ibogaine HCl; written narratives were thematically coded. Themes included oneiric visions, remorse/regret processing, and release from guilt and worthlessness—depression-*adjacent* experiential content, not a dedicated MDD RCT. Verification note: No separate Brown/Alper 2018 “depression secondary analysis” paper was identified; this 2019 subjective-experience paper is the closest citable Brown-line qualitative follow-on in-window, with related BDI depression outcomes documented in the paired Noller cohort. Route = oral (clinic/legal NZ settings)—not psychoactive IV ibogaine infusion. Not a cure claim. Ibogaine is U.S. Schedule I and not FDA-approved. QTc/cardiac risk remains central.

Quotable answer (58 words)

Brown, Noller, and Denenberg’s 2019 Journal of Psychoactive Drugs paper analyzed SCQ scores and narratives from 44 participants in the Brown–Alper Mexico and Noller New Zealand oral ibogaine OUD cohorts. Many met mystical-experience cutoffs; themes included release from guilt. Qualitative follow-on is not a depression cure trial and not psychoactive IV ibogaine infusion proof. Schedule I; screen for QTc.

Why this paper-spoke exists

Searchers type “ibogaine depression study Brown Alper” and expect a tidy secondary BDI paper. Inventory verification found no standalone Brown/Alper depression secondary circa 2018. What *does* exist—and what SEO should name accurately—is:

1. Brown & Alper 2018 quantitative OUD detox/drug-use outcomes (already /blog/brown-alper-2018-ibogaine-oud).
2. Noller 2018 12-month NZ observational with BDI-II depression secondary outcomes (already /blog/noller-2018-ibogaine-new-zealand; one death reported).
3. Brown, Noller & Denenberg 2019 subjective-experience follow-on pooling those cohorts’ experiential data.

This spoke covers (3), with honest cross-links to (1)–(2) depression/mood context. Soft CTA: /safety-and-screening → /apply.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Brown T.K., Noller G.E., Denenberg J.O. Ibogaine and Subjective Experience… *J Psychoactive Drugs*. 2019. doi 10.1080/02791072.2019.1598603. PMID 30967101 | | Type | Mixed qualitative + SCQ psychometric analysis (not RCT) | | Source cohorts | Mexico n=30 (Brown & Alper observational line); NZ n=14 (Noller observational line); combined experiential sample n=44 | | Route | Oral ibogaine HCl in clinic/legal-provider settings | | Instruments | States of Consciousness Questionnaire (SCQ); thematic coding of written transcripts | | Depression adjacency | Narrative themes of release from guilt and worthlessness; mystical/spiritual transformation—not MADRS/HAM-D primary endpoints | | Related depression numbers | See Noller 2018 BDI-II reductions (same NZ arm)—separate paper | | What it is not | MDD pivotal trial; FDA approval; psychoactive IV brand efficacy; cure claim |

Methods (plain language)

Participants from two previously reported oral-ibogaine OUD observational programs completed SCQ after treatment and provided written experience narratives. Researchers quantified “mystical experience” domain scores (commonly using a 0.6 domain cutoff for “complete” mystical experience) and iteratively coded themes. This design illuminates *what people report experiencing*, not whether ibogaine is a registered antidepressant.

Key findings (no hype)

• Mean SCQ scores in many domains exceeded the conventional 0.6 “complete mystical experience” cutoff; 43% of participants achieved that cutoff in more than five of seven domains.
• Qualitative themes included auditory and visual phenomena and cyclic, dream-like (oneiric) visions.
• Narratives described confronting remorse/regret toward others and release from guilt and worthlessness—emotionally salient content often confused online with “depression cured.”
• Authors argue oneiric/transformative effects may be a discrete element of reported healing, distinct from pharmacology of withdrawal/craving reduction.
• Design remains observational, self-report–heavy, and tied to clinic/legal settings that are not U.S. FDA care.

Honest reading: Mystical SCQ scores and guilt-release themes are meaningful phenomenology. They are not Level-1 evidence that ibogaine treats major depressive disorder, and they do not erase cardiac risk.

Depression outcomes: how to cite without inventing a paper

| Need | Correct citation path | |------|------------------------| | Brown-line OUD detox numbers | Brown & Alper 2018 (/blog/brown-alper-2018-ibogaine-oud) | | 12-month BDI-II depression secondary | Noller et al. 2018 (/blog/noller-2018-ibogaine-new-zealand) — note one treatment-associated death | | Large open-label BDI mood changes | Mash et al. 2018 Frontiers (/blog/mash-2018-ibogaine-detox-frontiers) | | Brown-line subjective/qualitative follow-on | This paper (Brown/Noller/Denenberg 2019) |

Do not invent a fictional “Brown & Alper 2018 Depression Follow-up” DOI. Name the real 2019 paper.

Route honesty & entity clarity

All source cohorts used oral ibogaine HCl. None establish physician-supervised psychoactive IV ibogaine infusion efficacy. IV magnesium or support fluids elsewhere in the literature are support, not the psychoactive dose (/blog/ibogaine-oral-vs-iv; /what-is-ibogaine-infusion).

Cardiac / YMYL context

Noller’s NZ program reported a death during treatment—already covered on the Noller spoke. Qualitative beauty does not cancel QTc biology. Pair with /blog/knuijver-2021-ibogaine-qtc-safety, /blog/ona-2022-ibogaine-adverse-events-review, /blog/ibogaine-mortality-cardiac-risk.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Not an RCT | Expectancy, selection, concurrent care | | Self-report SCQ/narratives | Recall and meaning-making bias | | Pooled clinic/legal settings | Not U.S. Schedule I clinical care | | Depression adjacency ≠ MDD trial | Guilt/worthlessness themes ≠ diagnostic remission criteria | | Oral≠IV | Brand IV cannot inherit this DOI as proof |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Brown Alper proved depression cured” | False | | “2019 paper is an MDD pivotal” | False | | “Proves psychoactive IV ibogaine” | False | | Useful phenomenology + SCQ context? | Yes—with labels |

Soft CTA

If experiential stories are pulling you toward treatment curiosity, start with cardiac reality: /safety-and-screening → then /apply only for supervised IV ibogaine infusion questions. Entity: /what-is-ibogaine-infusion.

FAQ

Is there a Brown & Alper 2018 depression secondary paper? No dedicated depression secondary was verified. Closest Brown-line qualitative follow-on is Brown/Noller/Denenberg 2019 (doi **10.1080/02791072.2019.1598603**).

What did the 2019 paper measure? SCQ mystical-experience domains plus thematic analysis of written ibogaine narratives from 44 OUD observational participants.

Did people report mood-related changes? Themes included release from guilt and worthlessness—experiential, not an MDD endpoint trial.

Where are BDI depression numbers? Noller 2018 (NZ cohort) and Mash 2018 report BDI-related mood outcomes in oral observational settings.

Was the route oral or IV ibogaine? **Oral** ibogaine HCl—not psychoactive IV ibogaine infusion.

Is this a cure for depression or addiction? No. Observational phenomenology; not FDA-approved; not a cure claim.

Does mystical experience remove cardiac risk? No. QTc screening remains mandatory.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Sources (selected)

1. Brown T.K., Noller G.E., Denenberg J.O. Ibogaine and Subjective Experience… *J Psychoactive Drugs*. 2019. doi: 10.1080/02791072.2019.1598603. PMID: 30967101.
2. Brown T.K., Alper K. Treatment of opioid use disorder with ibogaine… *Am J Drug Alcohol Abuse*. 2018;44(1):24–36. doi: 10.1080/00952990.2017.1320802.
3. Noller G.E. et al. Ibogaine treatment outcomes… *Am J Drug Alcohol Abuse*. 2018;44(1):37–46. doi: 10.1080/00952990.2017.1310218.
4. Mash D.C. et al. *Front Pharmacol*. 2018. doi: 10.3389/fphar.2018.00529.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Brown/Noller/Denenberg 2019 is qualitative/SCQ follow-on to oral OUD observational cohorts—not a depression cure trial and not psychoactive IV ibogaine efficacy proof.